{"id":21132,"date":"2025-01-09T23:56:42","date_gmt":"2025-01-09T15:56:42","guid":{"rendered":"https:\/\/flcube.com\/?p=21132"},"modified":"2025-01-09T23:56:45","modified_gmt":"2025-01-09T15:56:45","slug":"haier-biomedical-terminates-acquisition-plan-for-shanghai-raas","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21132","title":{"rendered":"Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS"},"content":{"rendered":"\n

Haier Biomedical (SHA: 688139<\/a>) has announced the termination of its plan to acquire Shanghai RAAS (SHE: 002252<\/a>), along with the associated share issuance for fundraising. The company cited the complex deal structure and the lack of a specific plan recognized by all parties involved as the reason for the termination, according to a stock exchange statement.<\/p>\n\n\n\n

Background of the Merger Agreement<\/strong>
The two companies signed an absorption and merger agreement of intent in late December of last year. The plan involved Haier Biomedical absorbing and merging with RAAS through the issuance of shares listed in China to all RAAS shareholders, and raising matching funds by issuing additional shares. At the time, Haier Biomedical had a market cap of RMB 10 billion (USD 1.34 billion), compared to RAAS’s market cap of RMB 50 billion (USD 6.82 billion). Haier Biomedical\u2019s stock resumed trading on January 7, 2025, after being suspended since December 31, 2024.<\/p>\n\n\n\n

Company Profiles<\/strong>
Founded in 2005, Haier Biomedical made its debut on the Shanghai Stock Exchange\u2019s Sci-Tech Innovation Board (STAR) in 2019. The company offers a range of products including blood separation equipment, testing equipment, and plasma consumables. RAAS, established in 1988, focuses on blood products. Both companies are controlled by China-based electronics and appliances firm Haier Group.<\/p>\n\n\n\n

Significance of the Termination<\/strong>
The termination of the acquisition plan highlights the challenges in executing complex corporate transactions, particularly in the context of significant market cap differences and intricate deal structures. This development underscores the importance of clear and mutually agreed-upon plans in facilitating successful mergers and acquisitions.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS…<\/p>\n","protected":false},"author":1,"featured_media":21135,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3104,3105,3106,1333],"class_list":["post-21132","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-haier-biomedical","tag-sha-688139","tag-shanghai-raas","tag-she-002252"],"yoast_head":"\nHaier Biomedical Terminates Acquisition Plan for Shanghai RAAS - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS (SHE: 002252), along with the associated share issuance for fundraising. The company cited the complex deal structure and the lack of a specific plan recognized by all parties involved as the reason for the termination, according to a stock exchange statement.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21132\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS\" \/>\n<meta property=\"og:description\" content=\"Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS (SHE: 002252), along with the associated share issuance for fundraising. The company cited the complex deal structure and the lack of a specific plan recognized by all parties involved as the reason for the termination, according to a stock exchange statement.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21132\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-09T15:56:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-09T15:56:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0925.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"602\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21132#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21132\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS\",\"datePublished\":\"2025-01-09T15:56:42+00:00\",\"dateModified\":\"2025-01-09T15:56:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21132\"},\"wordCount\":259,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21132#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0925.png\",\"keywords\":[\"Haier Biomedical\",\"SHA: 688139\",\"Shanghai RAAS\",\"SHE: 002252\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21132#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21132\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21132\",\"name\":\"Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21132#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21132#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0925.png\",\"datePublished\":\"2025-01-09T15:56:42+00:00\",\"dateModified\":\"2025-01-09T15:56:45+00:00\",\"description\":\"Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS (SHE: 002252), along with the associated share issuance for fundraising. The company cited the complex deal structure and the lack of a specific plan recognized by all parties involved as the reason for the termination, according to a stock exchange statement.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21132#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21132\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21132#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0925.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0925.png\",\"width\":1080,\"height\":602,\"caption\":\"Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21132#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS - Insight, China's Pharmaceutical Industry","description":"Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS (SHE: 002252), along with the associated share issuance for fundraising. The company cited the complex deal structure and the lack of a specific plan recognized by all parties involved as the reason for the termination, according to a stock exchange statement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21132","og_locale":"en_US","og_type":"article","og_title":"Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS","og_description":"Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS (SHE: 002252), along with the associated share issuance for fundraising. The company cited the complex deal structure and the lack of a specific plan recognized by all parties involved as the reason for the termination, according to a stock exchange statement.","og_url":"https:\/\/flcube.com\/?p=21132","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-09T15:56:42+00:00","article_modified_time":"2025-01-09T15:56:45+00:00","og_image":[{"width":1080,"height":602,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0925.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21132#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21132"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS","datePublished":"2025-01-09T15:56:42+00:00","dateModified":"2025-01-09T15:56:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21132"},"wordCount":259,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21132#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0925.png","keywords":["Haier Biomedical","SHA: 688139","Shanghai RAAS","SHE: 002252"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21132#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21132","url":"https:\/\/flcube.com\/?p=21132","name":"Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21132#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21132#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0925.png","datePublished":"2025-01-09T15:56:42+00:00","dateModified":"2025-01-09T15:56:45+00:00","description":"Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS (SHE: 002252), along with the associated share issuance for fundraising. The company cited the complex deal structure and the lack of a specific plan recognized by all parties involved as the reason for the termination, according to a stock exchange statement.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21132#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21132"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21132#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0925.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0925.png","width":1080,"height":602,"caption":"Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21132#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0925.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21132"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21132\/revisions"}],"predecessor-version":[{"id":21136,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21132\/revisions\/21136"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21135"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}